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Abstract 
Background: While LDL cholesterol measures the cholesterol content within an LDL particle (LDL-P), it may not reflect LDL-P 
concentrations. If discordance exists, LDL-P may better predict cardiovascular events compared to LDL-C and non-HDL cholesterol (non-
HDL-C). In primary prevention patients, discordance has been associated with diabetes, ethnicity, gender, metabolic syndrome, and 
smoking history.  
Objective: To describe discordance in patients of a lipid clinic by exploring associations between patient characteristics and discordance 
among LDL-C, non-HDL-C, or LDL-P. Secondarily to compare proportion of patients with baseline concordance versus discordance who 
have ASCVD events, diagnoses of new onset diabetes or death. 
Methods: A retrospective, single-center cohort study at a large academic medical center was conducted. Patients establishing care 
from January 2009 through December 2012 with complete initial labs were included. Logistic regression models were used to explore 
associations between discordance and patient characteristics. 
Results: Of 603 patients screened, the final cohort included 166 patients with 104 (62.7%) discordant. LDL-P was the most common 
discordant value. Discordance was associated with gender, smoking status, use of lipid lowering medications, and achieving patient 
specific LDL-C goals. In terms of any event observed after initial measurements, no significant differences were detected between 
discordant and concordant groups. 
Conclusion: Within a lipid clinic population, discordance was associated with male gender, smoking status, lipid-lowering therapy, and 
being at patient specific LDL-C goal. While associations were found in our population, clinicians should consider measuring LDL-P to 
fully assess presence or extent of discordance. 
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Background 
Cardiovascular disease in the United States accounts for 
600,000 deaths per year, translating to 1 in every 4 deaths.1 
Traditionally low-density lipoprotein cholesterol (LDL-C) has 
been used to determine risk of adverse cardiovascular events. 
However, despite current standards and achievement of Adult 
Treatment Panel (ATP) III defined LDL-C goals, patients with 
dyslipidemia remain at high risk of cardiovascular disease 
progression and clinical events.2, 3 This is particularly true for 
patients with established coronary heart disease, low high-
density lipoprotein cholesterol (HDL-C), diabetes mellitus type 
2, and metabolic syndrome.2, 3 In 2004, ATP III of the National  
 
Corresponding Author:  
Melissa J. Snider, PharmD, BCPS, CLS, BCACP  
Richard M. Ross Heart Hospital  
Ross Ambulatory Care Center, Room 1204E 
452 West 10th Avenue, Columbus, OH 43210 
Phone: 614.293.8470; Fax: 614.293.8260 
Email: Melissa.Snider@osumc.edu  
Cholesterol Education Program released a guideline, which 
served as the primary dyslipidemia guideline for many years.3, 4 
In recent years, many organizations have published clinical 
guidelines on the management of dyslipidemia.5-9 Each of these 
guidelines has a unique stance on cardiovascular risk 
assessment and targets of treatment. Despite differences in 
recommendations, each guideline agrees that LDL-C is 
important in identifying and assessing cardiovascular risk.  
 
Beyond identifying and assessing cardiovascular risk, LDL-C or 
non-HDL-C has been the primary target of therapy for 
cardiovascular risk reduction, and in some way, each guideline 
supports this recommendation. While LDL-C measures the 
cholesterol content within an LDL particle (LDL-P), it may not  
be reflective of the concentration of LDL-P. Evidence has 
suggested that when discordance is present between LDL-C, 
non-HDL-C, and LDL-P, concentration of LDL-P may better 
predict cardiovascular risk. 10-13 However, current guidelines do 
not endorse measurement of LDL-P for all patients, nor is it a 
primary target of therapy. Without the recommendation for 
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routine measurement in place, studies have attempted to 
determine patient characteristics that may be associated with 
discordance between LDL-C, non-HDL-C, or LDL-P. Discordance 
has been studied in healthy, statin-medication naïve, and 
primary prevention community patients. Within this 
population, discordance has been associated with gender, 
diabetes, smoking history, obesity, ethnicity, and metabolic 
syndrome.11,12, 14 In patients treated with lipid-lowering 
medication, discordance between LDL-C and LDL-P is enhanced 
as statin medications lower LDL-C to a greater extent than 
lowering LDL-P.15  Discordance has not been described in the 
setting of complex patients within a lipid clinic.  
 
The primary purpose of this study is to describe discordance in 
patients of a lipid clinic by exploring associations between 
patient characteristics and discordance between LDL-C, non-
HDL-C, or LDL-P. The secondary objective is to compare rates of 
composite and separate endpoints of ASCVD events, diagnoses 
of new onset diabetes, and/or death in patients with 
concordance versus discordance.  
 
Methods 
We conducted a retrospective, single-center cohort study at 
The Ohio State University Wexner Medical Center’s (OSUWMC) 
Cardiovascular Risk Reduction and Lipid Clinic. The OSUWMC 
health-system has over 1300-beds in a tertiary multidisciplinary 
academic medical center located in Columbus, OH. The Richard 
M. Ross Heart Hospital has over 150-beds specializing in 
cardiovascular medicine located on the OSUWMC’s campus. 
Within the Ross Heart Hospital, the Ross Ambulatory Care 
Center (ACC) is where patients are seen on an outpatient basis 
for cardiac and vascular conditions. There are several cardiology 
outreach sites in Columbus. The lipid clinics are referral based 
interdisciplinary cardiovascular risk reduction clinics 
established in 2007 and are located within Ross ACC, Carepoint 
Gahanna, and Carepoint East. In 2009, OSUWMC launched the 
Integrated Health Information System in the ambulatory care 
clinics. A physician and an ambulatory care specialty pharmacist 
staff the intake clinics collaboratively, while both a physician 
and pharmacist or a pharmacist acting under collaborative 
practice agreements staffs return clinics. Four physicians and 
eight pharmacists rotate throughout the seven weekly clinics. 
Approximately 1200 patients are seen within the lipid clinics 
each year. The study was exempt from The Ohio State 
University Institutional Review Board.  
 
Inclusion criteria included patients who: 1) established care in 
the lipid clinic within OSUWMC between January 1, 2009 and 
December 31, 2012, 2) obtained an initial traditional lipid profile 
and LDL-P, and 3) were 18-89 years of age. Exclusion criteria 
included patients who: 1) did not obtain initial visit LDL-P, 2) 
experienced a cardiovascular event within 30 days prior to 
obtaining initial lipid profiles, 3) did not return to OSUWMC for 
evaluation of cardiovascular health within the prior 18 months 
of the study end date, October 16, 2014, 4) were pregnant or 
imprisoned, and 5) had an incalculable LDL-C. Data were 
obtained using the OSUWMC electronic medical record, EPIC. 
The following patient characteristics were collected: gender, 
age, medical insurance, race, height, weight, body mass index, 
smoking status, primary or secondary cardiovascular 
prevention, cardiac family history, diabetes, impaired fasting 
glucose, waist circumference, hypertension, metabolic 
syndrome, initial LDL-C greater than 190 mg/dL, Framingham’s 
10-year risk assessment, Atherosclerotic Cardiovascular Disease 
(ASCVD) 10 year and lifetime risk assessment, goals of therapy, 
initial lipid-lowering medications, initial traditional lipid profile, 
and initial LDL-P measured by nuclear magnetic resonance 
(NMR). ATP III’s 2004 update or physician specified targets were 
used to individualize patient LDL-C and non-HDL-C.3 LDL-P goals 
were determined by assessing LDL-C and non-HDL-C goals and 
obtaining corresponding LDL-P goals based on an equivalent 
percentile. 16-18 ASCVD events, diagnosis of new onset diabetes 
mellitus, and death from any cause and death due to 
cardiovascular disease were also collected. The time a patient 
was followed in the study was recorded as well due variable 
follow-up periods. Definitions of data collection points are listed 
in appendix 1.  
 
The definition of discordance was defined by using the 2004 
National Cholesterol Education Program ATP III Update. LDL-C 
goals of 70 mg/dL, 100 mg/dL, 130 mg/dL, and 160 mg/dL 
corresponded to approximated population percentiles of 2nd, 
20th, 50th, and 80th for LDL-C in the Framingham Offspring 
Cohort.16, 17 Non-HDL-C and LDL-P percentiles correlate to the 
LDL-C thresholds and population percentiles outlined in the 
Framingham Offspring Cohort (Table 1). 16, 17 Discordance was 
identified if LDL-P, non-HDL-C, or LDL-C fell into a different 
population percentile. For example, if LDL-C and non-HDL-C fell 
between the 20th and 50th percentile, but LDL-P fell between the 
50th and 80th percentile the patient had discordant values.  
 
Statistical Analysis 
Descriptive statistics were generated for all variables of interest 
both overall and broken down by whether the patients’ values 
were discordant.  Continuous variables were expressed using 
means, standard deviations, medians and other appropriate 
measures of spread.  Categorical variables were expressed using 
frequencies and percentages.  Logistic regression models were 
used to estimate the relationship between various predictors 
and whether or not the patients’ baseline values were 
discordant.  Potential predictor variables were selected based 
on both the observed descriptive statistics and clinical 
relevance. Then, the relationship between potential predictor 
variables and concordance/discordance at initial visit was 
assessed individually using univariable logistic regression.  
Those variables that were statistically significant at 0.20 level 
were considered for inclusion in a multivariable model; these 
include gender, body mass index, current smoker, former 
smoker, history of myocardial infarction or coronary procedure, 
Framingham 10-year risk category, primary prevention, 
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currently on treatment, low HDL-C at baseline, LDL-C at goal at 
initial visit, and non-HDL-C at goal at initial visit. A backward 
selection approach was used to select a final multivariable 
model. All possible two-way interactions between the variables 
in the final model were considered and none were significant at 
the 0.01 level.  The proportion of patients who experienced an 
observed ASCVD event or death during the available follow-up 
period were reported both overall and broken down by 
concordant/discordance.  In addition, logistic regression models 
were used to estimate odds ratios for ASCVD events or death by 
discordance status adjusted by length of follow-up time. All 
analyses were performed using SAS 9.4, SAS Institute, Cary, 
North Carolina.   
 
Results 
There were 266 newly established patients within the lipid clinic 
from January 1, 2009 and December 31, 2012, and 166 of those 
met inclusion criteria (Figure 1). Among the thirty-one patients 
excluded for incalculable LDL-C, thirty patients had triglycerides 
> 400 mg/dL, and one patient had an LDL-C >400 mg/dL. Of the 
patients in the final cohort, 104 (62.7%) patients had discordant 
values compared to 62 (37.4%) patients with concordant values.  
 
Patients with discordant laboratory values were either 
discordant in one measure (i.e. two of the three values fell 
within the same percentile while one fell into a different 
percentile) or all three measures of LDL-C, non-HDL-C, and LDL-
P could fall within different percentiles. Among the discordant 
subgroup, 68 patients were discordant in one measure, and 
among these patients, LDL-P fell into the different population 
patient percentile for 43 (63.2%) patients whereas LDL-C was 
different for 17 patients (25%). Of the 43 patients where LDL-P 
was the unique discordant value, LDL-P fell into the higher 
population patient percentile for 36 (86.1%) patients. Among 
the 36 patients with discordant laboratory values across all 
three measurements, LDL-P fell into the highest population 
patient percentile for 31 (86.1%) patients; LDL-C never fell into 
the highest percentile when all three values differed.  
 
Baseline demographics were summarized both overall as well 
as for the concordant and discordant subgroups, separately 
(Table 2). Overall, males comprised 54.8% of the cohort; 62.5% 
of the discordant subgroup was male compared to 41.9% of the 
concordant subgroup. The average age of the cohort was 51.6 
years (range 18 – 82) with the majority of patients being 
Caucasian (83.1%). A large proportion of patients presented 
with metabolic syndrome (69.9%), hypertension (68.1%), and 
on lipid lowering therapy (66.3%) compared to the less 
frequently observed diabetes (23.5%), impaired fasting glucose 
(40.4%), and currently smoking (20.5%).  Of the 110 patients on 
medications, 61 (55.5%) patients were taking two or more 
medications.  
 
Within the concordant subgroup, a larger proportion of patients 
were primary prevention (74.2%) compared to the discordant 
subgroup (58.7%); whereas within the discordant subgroup, 
more individuals were utilizing lipid-lowering therapies (77.9%) 
compared to the concordant subgroup (46.8%). In addition, a 
larger proportion of patients with discordant laboratory values 
had achieved LDL-C goals (42.3%) and non-HDL-C goals (32.7%) 
at initial visit compared to patients who achieved LDL-C goals 
(11.3%) and non-HDL-C (11.3%) goals in the concordant 
subgroup.  
 
Characteristics included in the final multivariable logistic 
regression model were gender, body mass index, current 
smoker, former smoker, history of myocardial infarction or 
coronary procedure, Framingham 10-year risk category, 
primary prevention, currently on treatment, low HDL-C at 
baseline, LDL-C at goal at initial visit, and non-HDL-C at goal at 
initial visit. Among these, the following were included in the 
final multivariable logistic regression model: gender, current 
and former smoker, on treatment at initial visit, and LDL-C at 
goal at initial visit.  
 
Within the cohort, the odds of having a discordant laboratory 
value were significantly higher for males, current smokers, 
former smokers, patients currently on treatment at initial visit, 
and patients at their LDL-C goal at initial visit (Table 3). For 
instance, the odds of having a discordant laboratory value were 
3.93 times higher for those individuals utilizing lipid-lowering 
therapies compared to those who were not. Interestingly, for 
patients who achieved LDL-C goals at initial visit the odds of 
having a discordant laboratory value were 7.31 times higher 
than those who were not at LDL-C goal at initial visit.  
 
For the secondary objective, observed diagnoses of new onset 
diabetes, ASCVD events, death due to cardiovascular disease, 
and non-cardiovascular death are represented in Table 4. The 
length of follow-up was variable for each patient; the minimum 
follow-up time was 1.3 years and the maximum follow-up time 
was 4.9 years. Among the concordant and discordant 
subgroups, 7 (11.3%) and 21 (20.2%) patients, respectively, 
experienced some type of event – ASCVD event, diagnosis of 
new onset diabetes or death – during their observed follow-up 
time. Upon adjusting for length of follow-up time, no significant 
difference was detected between discordant and concordant 
subgroups (OR 1.99, 95% CI 0.79 – 5.00). Similarly, ASCVD 
events or diagnoses of new onset diabetes were observed in the 
concordant subgroup for                6 individuals (9.7%) compared 
to 19 individuals (18.3%) in the discordant subgroup. Again, 
after adjusting for length of follow-up, no significant difference 
was detected between discordant and concordant subgroups 
(OR 2.09, 95% CI 0.78 – 5.55). One patient died from non-
cardiovascular complications in the concordant subgroup 
whereas four patients died from cardiovascular complications 
in the discordant subgroup during the observed follow-up 
period.   
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Discussion 
Discordance was associated with male gender, current and 
former smokers, currently on lipid lowering therapy at initial 
clinic visit, and being at patient specific LDL-C goal at initial clinic 
visit. Within our cohort, these associations indicate that 
discordance is more likely when certain patient characteristics 
are present. For example, a male presenting to clinic is more 
likely to have a discordant value compared to a female, and a 
patient on a lipid lowering medication at initial visit is more 
likely to have a discordant value than a patient without 
pharmacologic lipid lowering therapy.  
 
With respect to current guidelines, the ACC/AHA Lipid 
Management guidelines recommend statin therapy, often at 
moderate or high intensity, for patients of statin benefit groups 
with a goal of 30-50% LDL-C reduction.6 The National Lipid 
Association (NLA) Lipid Management guidelines recommend 
targeting non-HDL-C as the primary goal for cardiovascular risk 
reduction through lipid management.9 In regards to advanced 
lipoprotein testing, several organizations have endorsed the 
measurement of LDL-P as secondary goals of therapy or as 
additional assessments of residual cardiovascular risk.9, 19-21 NLA 
acknowledges that the measurement of LDL-P can be clinically 
useful especially once non–HDL-C and LDL-C goals have been 
attained.9 Furthermore, the Inflammatory Markers and 
Advanced Lipoprotein expert panel states that LDL-P 
measurement is reasonable for many patients including those 
patients with: 1) an intermediate risk of cardiovascular disease 
and treated to LDL-C and non-HDL-C goal 2) cardiovascular 
disease on lipid-lowering therapy 3) cardiovascular risk 
equivalents defined by ATP III on lipid-lowering therapy, and 4) 
recurrent cardiovascular events. 4, 19 Finally, a recent report 
indicates that measurement and assessment of LDL-P among 
non-statin benefit group patients is useful in determining 
overall cardiovascular risk.22 Measurement of LDL-P is optimal 
in order to fully assess the presence and extent of discordance 
as well as cardiovascular risk.  
 
It is well established that when discordance exists, LDL-P better 
predicts cardiovascular risk. 10-13 Measuring and targeting both 
LDL-C and LDL-P compared to LDL-C alone has been proven to 
be a cost-effective approach for the healthcare-system.23  
Despite this, LDL-P is not routinely assessed due to varying third 
party-payer reimbursement models, availability of laboratory 
tests, and lack of consistency in recognition as a standard of 
care across lipid management guidelines; measuring and 
assessing LDL-C and non-HDL-C remain the standard of care.5-9, 
23 If one could reliably predict discordance, this could provide 
health-care professionals a convenient and efficient method in 
identifying cardiovascular risk and managing dyslipidemia.   
 
The results of the current study support previously defined 
associations between patient characteristics and discordance 
among laboratory values, while at the same time, presents new 
associations. Discordance has previously been associated with 
age, gender, diabetes mellitus, ethnicity, metabolic syndrome, 
smoking status, obesity, and private insurance. 11, 12, 14 The 
results of the current study support the association between 
discordance and gender that was found by Otvos, et al., as well 
as the association between discordance and smoking status 
found by Kilgore, et al. 11, 14 However, the current study also 
found that discordance was associated with lipid lowering 
therapy and achievement of LDL-C goals at initial visit. When 
considering discordance among patients being treated with 
lipid lowering therapy, Rosenson, et al. indicated that 
discordance between LDL-C and LDL-P is enhanced as statin 
medications lower LDL-C to a great extent than lowering LDL-
P.15 It is evident that certain patient characteristics may be 
associated with discordance.  
 
The current study is the first to look at a description of 
discordance in a lipid clinic, being based on patient 
characteristics in complex patients who are being evaluated for 
cardiovascular disease or are being treated with lipid lowering 
therapies. Additionally, it is the first to look at patient 
characteristics associated with discordance between three 
variables together of LDL-C, non-HDL-C, and LDL-P.  
 
While event rates were low in the current study, previous 
literature has reported that patients with discordance have a 
higher degree of cardiovascular risk.10-13  In this study, LDL-P was 
found to be in the highest population percentile for the majority 
of patients when discordance was present.  Additionally, 
although not significantly different, the discordant subgroup did 
have more observed non-death related ASVCD events, 
diagnoses of diabetes, and deaths due to cardiovascular 
complications compared to the concordant subgroup.  
 
Limitations to the current study include the single-center, 
retrospective study design as well as the small population size.  
The single-center design is a limitation of the study as these 
patients may have different characteristics than other 
populations.  Although the results of this study may not be 
directly applicable to other cohorts of patients, our results are 
somewhat consistent with what others have observed.  The 
retrospective nature of the study is a limitation because we 
were only able to include patients who had the full lipid 
assessment.  While the lipid clinic’s protocols suggest that at 
initial clinic visit every patient have a LDL-P drawn, every 
provider did not routinely draw this for every patient, creating 
a selection bias. Additionally, the small population size makes 
the application of this to lipid patients across regions of the 
country difficult as patient populations may vary. Furthermore, 
concordance and discordance was assessed at a single point in 
time, the initial visit to lipid clinic. Application of clinical 
outcomes in this study is limited due to low event rate, and 
variable follow-up times; those patients with longer follow-up 
times had more opportunities to experience an observed event 
or death compared to those with shorter follow-up. It is also a 
limitation that some patients included in the secondary 
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outcome based on initial concordance or discordance may 
become the opposite while on treatment.  
 
Prospective research is needed to determine if patient 
characteristics can reasonably predict discordance between 
LDL-C, non-HDL-C, and LDL-P. Additionally, prospective studies 
are also necessary to examine whether a patient may fluctuate 
between concordance and discordance over a period of time as 
well as determining if knowledge of discordance at initial visit 
and subsequent therapy changes are associated with improved 
clinical outcomes. Further research is also needed to identify 
specific lipid-lowering therapies that may or may not be 
associated with discordance as well as how combination 
therapy affects discordance. 
 
Within a lipid clinic population, discordance was associated with 
male gender, current or former smokers, lipid-lowering 
therapy, and being at patient specific LDL-C goal. Until these or 
other associations can be explored as predictive, clinicians 
should consider measuring LDL-P in patients to assess the 
presence or extent of discordance.  
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Table 1 Definition of Discordance17 
Percentile LDL-C (mg/dL) Non-HDL-C (mg/dL) LDL-P (mmol/L) 
˂ 2 ˂ 70 ˂ 83 ˂ 720 
2 - ˂ 20 70 - 99 83 - 118 720 - 1099 
20 - ˂ 50 100 - 129 119 - 152 1100 - 1439 
50 - ˂ 80 130 - 159 153 - 186 1440 - 1819 
≥ 80 ≥ 160 ≥ 187 ≥ 1820 
 
 
 
 
Figure 1 Study Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1759 patient encounters in lipid clinic from 
January 1, 2009 and December 31, 2012 
603 unique patients seen in lipid clinic 
266 patients newly established care in 
 lipid clinic 
166 patients included in final cohort 
Exclusion Criteria: 
• Age n=1 
• Missing LDL-P n=2 
• Incalculable LDL-C n=31 
• Loss to follow-up n=66 
 
104 discordant 
62 concordant 
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Table 2: Baseline Patient Characteristics for Total Cohort, Concordant Subgroup, and Discordant Subgroup 
Variable Concordant  (n=62) Discordant  (n=104) Total  N=(166) 
Male, n (%) 26 (41.9%) 65 (62.5%) 91 (54.8%) 
Age, mean (SD) [range] 51.4 (12.2) [24 – 82] 51.7 (11.4) [18 – 75] 51.6 (11.7) [18 – 82] 
BMI, mean (SD) [range] 30.2 (6.1) [20.7 – 48.8] 32.3 (6.9) [21.8 – 63.9] 31.5 (6.7) [20.7 – 63.9] 
Waist Circumferencea, mean (SD) [range] 37.9 (5.6) [26 – 55] 40.6 (5.5) [30 – 61] 39.6 (5.7) [26 – 61]  
Race 
   Caucasian, n (%) 
   African American, n (%)  
   Other, n (%) 
 
51 (82.3%) 
8 (12.9%) 
3 (4.8%) 
 
87 (83.7%) 
13 (12.5%) 
4 (3.9%) 
 
138 (83.1%) 
21 (12.7%) 
7 (4.2%) 
Diabetes mellitus, n (%) 12 (19.4%) 27 (26.0%) 39 (23.5%) 
Impaired fasting glucose, n (%) 22 (35.5%) 45 (43.3%) 67 (40.4%) 
Current smoker, n (%) 9 (14.5%) 25 (24.0%) 34 (20.5%) 
Former smoker, n (%) 11 (17.7%) 35 (33.7%) 46 (27.7%) 
Metabolic syndrome, n (%) 40 (64.5%) 76 (73.1%) 116 (69.9%) 
History of myocardial infarction, n (%) 9 (14.5%) 20 (19.2%) 29 (17.5%) 
History of stroke/transient ischemic attack, n (%) 3 (4.8%) 5 (4.8%) 8 (4.8%) 
History of coronary procedure, n (%) 16 (25.8%) 39 (37.5%) 55 (33.1%) 
History of vascular disease or procedure, n (%) 0 (0.0%) 2 (1.9%) 2 (1.2%) 
Cardiovascular family history, n (%) 32 (51.6%) 54 (51.9%) 86 (51.8%) 
Diagnosis of hypertension or medications, n (%) 39 (62.9%) 74 (71.2%) 113 (68.1%) 
Statin intolerant, n (%) 20 (32.3%) 22 (21.2%) 42 (25.3%) 
ASCVD 10 year riskb 
   0 - < 5, n (%) 
   5 - < 7.5, n (%) 
   > 7.5, n (%) 
 
   12 (19.4%) 
   5 (8.1%) 
   33 (53.2%) 
 
   15 (14.4%) 
   10 (9.6%) 
   62 (59.6%) 
 
   27 (16.3%) 
   15 (9.0%) 
   95 (57.2%) 
ASCVD lifetime riskb 
   0 - < 5, n (%) 
   5 - < 7.5, n (%) 
   > 7.5, n (%) 
 
   0 (0.0%) 
   0 (0.0%) 
   48 (77.4%) 
 
   0 (0.0%) 
   0 (0.0%) 
   73 (70.2%) 
 
   0 (0.0%) 
   0 (0.0%) 
   121 (72.9%) 
Framingham 10 year risk  
   0 - < 10, n (%) 
   10 - 20, n (%) 
   >20, n (%) 
 
   29 (46.8%) 
   11 (17.7%) 
   22 (35.5%) 
 
   34 (32.7%) 
   14 (13.5%) 
   56 (53.9%) 
 
   63 (38.0%) 
   25 (15.1%) 
   78 (47.0%) 
Private insurance payer 44 (71.0%)c 76 (73.1%) 120 (72.3%) 
Primary prevention, n (%) 46 (74.2%) 61 (58.7%) 107 (64.5%) 
Treatment at initial visit, n (%) 
   1 treatment, n (%) 
   2+ treatments, n (%) 
   High-intensity statin, n (%) 
   Moderate-intensity statin, n (%)  
   Low-intensity statin, n (%) 
   Ezetimibe, n (%) 
   Bile Acid Sequestrants, n (%) 
   Fibrates, n (%) 
   Fish-Oil, n (%) 
   Niacin, n (%) 
29 (46.8%) 
   16 (55.2%) 
   13 (44.8%) 
   5 (17.2%) 
   8 (27.6%) 
   1 (3.5%) 
   2 (6.9%) 
   1 (3.5%) 
   6 (20.7%) 
   16 (55.2%) 
   9 (31.0%) 
81 (77.9%) 
   33 (40.7%) 
   48 (59.3%) 
   25 (30.9%) 
   31 (38.3%) 
   7 (8.6%) 
   14 (17.3%) 
   2 (2.5%) 
   29 (35.8%) 
   26 (32.1%) 
   14 (17.3%) 
110 (66.3%) 
   49 (44.6%) 
   61 (55.5%) 
   30 (27.3%) 
   39 (35.5%) 
   8 (7.3%) 
   16 (14.6%) 
   3 (2.7%) 
   35 (31.8%) 
   42 (38.2%) 
   23 (20.9%) 
Low HDL at initial visitd, n (%) 17 (27.4%) 45 (43.3%) 62 (37.4%) 
LDL-C >190 at initial visit, n (%) 21 (33.9%) 3 (2.9%) 24 (14.5%) 
High triglycerides at initial visite, n (%) 29 (46.8%) 65 (62.5%) 94 (56.6%) 
Goal at initial visit: LDL-Pf, n (%) 3 (4.8%) 11 (10.6%) 14 (8.4%) 
Goal at initial visit: LDL-Cf, n (%) 7 (11.3%) 44 (42.3%) 51 (30.7%) 
Goal at initial visit: non-HDL-Cf, n (%) 7 (11.3%) 34 (32.7%) 41 (24.7%) 
a 9 patients did not have a waist circumference recorded 
b 29 patients did not have a calculated ASCVD 10 year risk score due to an age <40 or >79 years of age and 45 patients did not have a calculated ASCVD Lifetime risk 
score due to ages <20 or >59 years of age 
c Insurance type for five patients within concordant group was unknown  
d Low HDL defined as HDL <40 for males and HDL <50 for females 
e High triglycerides defined as triglycerides >150 
f LDL-C and non-HDL-C goals were determined by ATP III Guidelines, and LDL-P goals were equivalent to LDL-C and non-HDL-C population percentiles.  
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Table 3: Odds Ratios of Patient Variables and Discordance 
Variable Odds Ratio 95% CI p-value 
Gender:  Male vs. Female 2.38 (1.12, 5.07) 0.025 
Current Smoker:  Yes vs. No 3.62 (1.35, 9.68) 0.011 
Former Smoker:  Yes vs. No 3.04 (1.21, 7.63) 0.018 
Currently on Treatment:  Yes vs. No 3.93 (1.83, 8.45) 0.0005 
At Goal at Baseline: LDL-C:  Yes vs. No 7.31 (2.72, 19.64) <0.0001 
 
 
 
 
 
 
 
 
 
Table 4: Secondary Outcomes between Concordant and Discordant Subgroups 
Variable Concordant 
(n=62) 
Discordant 
(n=104) 
Total 
(N=166) 
Any non-death eventa, n (%) 6 (9.7%) 19 (18.3%) 25 (15.1%) 
Diagnosis of new onset diabetes mellitus, n (%) 4 (6.5%) 7 (6.7%) 11 (6.6%) 
ASCVD Events 
   Myocardial infarction, n (%) 
   Stroke/transient ischemic attack, n (%) 
   Coronary procedure, n (%) 
   Vascular disease or procedure, n (%) 
 
1 (1.6%) 
0 (0.0%) 
3 (4.8%) 
0 (0.0%) 
 
4 (3.9%) 
1 (1.0%) 
11 (10.6%) 
0 (0.0%) 
 
5 (3.0%) 
1 (0.6%) 
14 (8.4%) 
0 (0.0%) 
Any ASCVD Events 3 (4.8%) 13 (12.5%) 16 (9.6%) 
Death  
   Non- cardiovascular death, n (%) 
   Cardiovascular death, n (%) 
 
1 (1.6%) 
0 (0.0%) 
 
0 (0.0%) 
4 (3.9%) 
 
1 (0.6%) 
4 (2.4%) 
Total Death  1 (1.6%) 4 (3.9%) 5 (3.0%) 
a Composite endpoint representing number of patients that had an ASCVD event or diagnoses of new onset diabetes  
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Appendix 1 – Data Collection Definitions 
Data Collection Point Definition  
Gender Male or Female 
Age Defined at initial visit  
Ethnicity Non-Hispanic or Latino 
Race Caucasian, African Americans, Asian  
Insurance Status Patient’s medical insurance at the time of initial visit 
Smoking History Current smoking history will include cigarettes, cigars, and chewing 
tobacco. Former tobacco users will also be recorded  
Primary Prevention Patient has not experienced a cardiovascular event 
Secondary Prevention  Patient has already experienced a cardiovascular event 
Cardiovascular event Cardiovascular events include myocardial infarctions,  
Cardiac Family History Family history is defined as premature coronary heart disease in a first 
degree relative if male <55 years and females <65 according to Adult 
Treatment Panel (ATP) III Guidelines 
Diabetes  A1c > 6.5 according to American Diabetes Association or the use of 
diabetic medications 
Impaired Fasting Glucose Fasting glucose > 100 
Hypertension Diagnosis listed in problem list, antihypertensive medications on 
medication profile or BP ≥ 135/85 at initial visit   
According to ATP III Guidelines, patient must meet 3 of 5: 
Waist Circumference > 40 inches for males and >35 inches for females 
Triglycerides > 150 mg/dL 
BP ≥ 135/85 
Low HDL <40 mg/dL in men and <50 mg/dL for females  
Impaired Fasting Glucose >100 mg/dL 
Framingham’s 10-year risk assessment Calculation using the online NHLBI tool that estimates cardiovascular 
event risk during a 10 year period and can aid in determination of LDL 
targets of therapy according to ATP III Guidelines 
ASCVD 10-year and lifetime risk assessment ASCVD stands for Atherosclerotic Cardiovascular Disease 
ASCVD 10 year and lifetime risk are calculations that estimates 
cardiovascular event risk and can aid in the determination of targets of 
therapy according to the American Heart Association/American 
College of Cardiology (AHA/ACC) Guideline on the Assessment of 
Cardiovascular Risk 
Goals of Therapy Goals of therapy are patient specific recommendations for low density 
lipoproteins cholesterol (LDL-C), non-high density lipoproteins 
cholesterol (HDL-C), and low density lipoprotein particles (LDL-P) 
Initial cholesterol-lowering medications Identification of cholesterol medications currently used when 
presenting initially to clinic as well as classification of statin therapy 
based on 2013 AHA/ACC Assessment of Cardiovascular Risk 
Traditional Lipid Profile Traditional lipid profile includes measurement of total cholesterol, LDL-
C, HDL-C, and triglycerides. Non-HDL-C can be calculated by 
subtracting HDL from total cholesterol.  
ASCVD Events ASCVD events are defined as coronary heart disease (CHD), stroke, and 
peripheral artery disease. Specifically looking for myocardial 
infarctions, stroke, trans-ischemic attack (TIA), coronary procedures, 
and diagnosis of vascular disease or vascular procedure  
 
